Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company's proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.
Work at Aspect Biosystems in HR or recruiting? Claim this page
Headcount trend
Aspect Biosystems went from 96 employees in Oct 2024 to 124 in Sep 2026. Apr to Sep 2026: 18 people joined, 8 left.
Funding rounds
| Date | Round | Money raised | No. | Investors |
|---|---|---|---|---|
| Jan 2020 | Series A | $20M | 4 | |
| Nov 2018 | Funding | $2.7M | – | – |
| May 2018 | Venture | $1M | 1 | |
| Sep 2017 | Funding | – | 4 | |
| Jul 2017 | Angel | – | 1 |
Org structure
Headcount by department
Peer reviews
Worked with someone at Aspect Biosystems?
Anonymous peer reviews on OffTheRecord
Similar companies
Aspect Biosystems FAQ
How many employees does Aspect Biosystems have?
Aspect Biosystems has about 124 employees, unchanged over the 3 months to Sep 2026.
What is Aspect Biosystems's revenue per employee?
Aspect Biosystems makes about $52K in revenue per employee, based on $6.5M annual revenue and 124 employees.
How much funding has Aspect Biosystems raised?
Aspect Biosystems has raised $23.7M in total funding; its latest round was Series A in Jan 2020.
Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.